CEO Cedric Francois was paid $10,957,451 in fiscal year 2024, ↑ up 5.6% from fiscal year 2023, the 38th percentile of its disclosed peer group (SEC filing 0000950170-25-056966 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$10,957,451 ↑ Cedric Francois total, FY2024 | 38th CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Cedric Francois | $793,193 | $580,736 | $4,779,832 | $4,787,768 | $0 | $0 | $15,922 | $10,957,451 |
| President & Chief Executive Officer | ||||||||
| Caroline Baumal | 610,386 | 279,026 | 1,687,004 | 1,689,790 | 0 | 0 | 140,922 | 4,407,128 |
| Chief Medical Officer | ||||||||
| Adam Townsend | 542,732 | 249,535 | 1,574,492 | 1,577,122 | 0 | 0 | 12,172 | 3,956,053 |
| Chief Commercial Officer | ||||||||
| Timothy Sullivan | 530,963 | 242,730 | 1,574,492 | 1,577,122 | 0 | 0 | 23,768 | 3,949,075 |
| Chief Financial Officer | ||||||||
| David Watson | 513,078 | 211,107 | 1,574,492 | 1,577,122 | 0 | 0 | 15,922 | 3,891,721 |
| General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Cedric Francois | $10,957,451 | $10,373,049 | $9,203,556 | ↑ +584,402 |
| Caroline Baumal | 4,407,128 | 4,430,459 | — | ↓ −23,331 |
| Adam Townsend | 3,956,053 | 3,714,246 | 3,096,029 | ↑ +241,807 |
| Timothy Sullivan | 3,949,075 | 3,737,235 | 3,546,148 | ↑ +211,840 |
| David Watson | 3,891,721 | 4,885,889 | 3,069,773 | ↓ −994,168 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Apellis Pharmaceuticals, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper APLS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Apellis Pharmaceuticals, Inc. Peer Teardown Report
$10,957,451 Cedric Francois total, FY2024
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of April 28, 2026 · Source: 0000950170-25-056966 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for APLS
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order APLS
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name APLS as a peer is temporarily unavailable — recheck shortly.
Get the Apellis Pharmaceuticals, Inc. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| A. Sinclair Dunlop | Independent Director | $477,465 |
| Alec Machiels | Independent Director | $492,465 |
| Gerald Chan | Independent Director | $498,715 |
| Paul Fonteyne | Independent Director | $487,465 |
| Stephanie Monaghan O'Brien | Director | $484,965 |
Equity transactions since the proxy statement are temporarily unavailable — recheck shortly.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Timothy Sullivan | OPTION | 2024-01-16 | — | — | 34,533 | — | $1,577,122 |
| David Watson | OPTION | 2024-01-16 | — | — | 34,533 | — | 1,577,122 |
| Caroline Baumal | RSU | 2024-01-16 | — | — | 25,445 | — | 1,687,004 |
| David Watson | RSU | 2024-01-16 | — | — | 23,748 | — | 1,574,492 |
| Cedric Francois | OPTION | 2024-01-16 | — | — | 104,834 | — | 4,787,768 |
| Adam Townsend | OPTION | 2024-01-16 | — | — | 34,533 | — | 1,577,122 |
| Cedric Francois | RSU | 2024-01-16 | — | — | 72,094 | — | 4,779,832 |
| Timothy Sullivan | RSU | 2024-01-16 | — | — | 23,748 | — | 1,574,492 |
| Adam Townsend | RSU | 2024-01-16 | — | — | 23,748 | — | 1,574,492 |
| Caroline Baumal | OPTION | 2024-01-16 | — | — | 37,000 | — | 1,689,790 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Timothy Sullivan | $1,574,492 | $0 | $1,577,122 | 0.0% |
| David Watson | 1,574,492 | 0 | 1,577,122 | 0.0% |
| Caroline Baumal | 1,687,004 | 0 | 1,689,790 | 0.0% |
| Cedric Francois | 4,779,832 | 0 | 4,787,768 | 0.0% |
| Adam Townsend | 1,574,492 | 0 | 1,577,122 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Caroline Baumal | Option | 25,521 | 50.28 | — |
| David Watson | RSU | 17,969 | — | 573,391 |
| Caroline Baumal | RSU | 26,662 | — | 850,784 |
| Timothy Sullivan | RSU | 20,616 | — | 657,857 |
| Cedric Francois | RSU | 72,094 | — | 2,300,520 |
| Cedric Francois | RSU | 62,586 | — | 1,997,119 |
| Cedric Francois | RSU | 60,076 | — | 1,917,025 |
| David Watson | RSU | 40,092 | — | 1,279,336 |
| Caroline Baumal | RSU | 25,445 | — | 811,950 |
| Timothy Sullivan | RSU | 23,748 | — | 757,799 |
| David Watson | RSU | 23,748 | — | 757,799 |
| Adam Townsend | RSU | 23,748 | — | 757,799 |
| Timothy Sullivan | RSU | 21,236 | — | 677,641 |
| Adam Townsend | RSU | 20,616 | — | 657,857 |
| Adam Townsend | RSU | 17,969 | — | 573,391 |
| Cedric Francois | RSU | 6,250 | — | 199,438 |
| Timothy Sullivan | RSU | 1,875 | — | 59,831 |
| David Watson | RSU | 1,875 | — | 59,831 |
| Adam Townsend | RSU | 1,875 | — | 59,831 |
| Cedric Francois | Option | 104,834 | 66.3 | — |
| Cedric Francois | Option | 68,278 | 52.66 | — |
| Cedric Francois | Option | 46,150 | 35.46 | — |
| Cedric Francois | Option | 3,125 | 44.9 | — |
| Timothy Sullivan | Option | 34,533 | 66.3 | — |
| Timothy Sullivan | Option | 22,492 | 52.66 | — |
| Timothy Sullivan | Option | 16,317 | 35.46 | — |
| Timothy Sullivan | Option | 938 | 44.9 | — |
| Caroline Baumal | Option | 37,000 | 66.3 | — |
| David Watson | Option | 34,533 | 66.3 | — |
| David Watson | Option | 19,640 | 52.66 | — |
| David Watson | Option | 13,808 | 35.46 | — |
| David Watson | Option | 938 | 44.9 | — |
| Adam Townsend | Option | 34,533 | 66.3 | — |
| Adam Townsend | Option | 22,492 | 52.66 | — |
| Adam Townsend | Option | 13,808 | 35.46 | — |
| Adam Townsend | Option | 938 | 44.9 | — |
Our compensation program is designed to attract, motivate and retain qualified and talented executives, motivating them to achieve our business goals and rewarding them for superior short- and long-term performance. The program aligns the interests of our executive officers with those of our stockholders to increase stockholder value, with a significant portion of compensation being variable and at risk, tied to stock price performance or achievement of pre-set performance objectives.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Say-on-pay vote history is temporarily unavailable — recheck shortly.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gerald ChanIndependent | $98,750 | $199,992 | $199,973 | — | — | $498,715 |
| Alec MachielsIndependent · Audit (Chair) · Compensation · Compliance | 92,500 | 199,992 | 199,973 | — | — | 492,465 |
| Paul FonteyneIndependent · Audit | 87,500 | 199,992 | 199,973 | — | — | 487,465 |
| Stephanie Monaghan O'BrienNot independent | 85,000 | 199,992 | 199,973 | — | — | 484,965 |
| A. Sinclair DunlopIndependent · Audit · Nominating and Corporate Governance | 77,500 | 199,992 | 199,973 | — | — | 477,465 |
| Cedric FrancoisEmployee director | — | — | — | — | — | 0 |
| Craig WheelerIndependent · Newly elected | — | — | — | — | — | — |
| Keli WalbertIndependent · Compensation · Compliance · Nominating & Corporate Governance · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 12,500 / 10,000 / 7,500 |
| Stock ownership guideline | $150,000 |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $441,250 |
| Equity awards (grant-date value) | $999,960 |
| All other compensation | $0 |
| Total cost of the board | $1,441,210 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Apellis Pharmaceuticals, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Apellis Pharmaceuticals, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 3 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | Insmed Incorporated | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 5 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 6 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 7 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 4,297,208 | 4,147,630 | 1,438,105 | 13,350,777 |
| 8 | Biocryst Pharmaceuticals, Inc | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 9 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 10 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 11 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 12 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 13 | ACADIA Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| ACADIA Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Biocryst Pharmaceuticals, Inc | not disclosed | not disclosed | not disclosed | Aon |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Insmed Incorporated | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Madrigal Pharmaceuticals, Inc. | 195% | PSU 33 · RSU 33 · Options 33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia |
| Neurocrine Biosciences | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Cedric Francois | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Executive Compensation”. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 2 | Section 01, Caroline Baumal | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Executive Compensation”. As printed: 4,407,128. Filing ↗machine: r8 · c25 · span 1003912–1003921 |
| 3 | Section 01, Adam Townsend | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Executive Compensation”. As printed: 3,956,053. Filing ↗machine: r13 · c25 · span 1047537–1047546 |
| 4 | Section 01, Timothy Sullivan | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Executive Compensation”. As printed: 3,949,075. Filing ↗machine: r5 · c25 · span 977730–977739 |
| 5 | Section 01, David Watson | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Executive Compensation”. As printed: 3,891,721. Filing ↗machine: r10 · c25 · span 1021390–1021399 |
| 6 | Section 03, Timothy Sullivan OPTION | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r4 · c3 · span 846013–846019 |
| 7 | Section 03, David Watson OPTION | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t20 · r10 · c17 · span 1018861–1018870 |
| 8 | Section 03, Caroline Baumal RSU | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r5 · c7 · span 849916–849922 |
| 9 | Section 03, David Watson RSU | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t20 · r10 · c13 · span 1017595–1017604 |
| 10 | Section 03, Cedric Francois OPTION | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r3 · c3 · span 843275–843282 |
| 11 | Section 03, Adam Townsend OPTION | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t20 · r13 · c17 · span 1045008–1045017 |
| 12 | Section 03, Cedric Francois RSU | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r3 · c7 · span 844443–844449 |
| 13 | Section 03, Timothy Sullivan RSU | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r4 · c7 · span 847180–847186 |
| 14 | Section 03, Adam Townsend RSU | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t20 · r13 · c13 · span 1043742–1043751 |
| 15 | Section 03, Caroline Baumal OPTION | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES” · grants of plan-based awards table. Filing ↗machine: t18 · r5 · c3 · span 848749–848755 |
| 16 | Section 08, Gerald Chan | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Director Compensation”. As printed: 498,715. Filing ↗machine: span 484609–484818 |
| 17 | Section 08, Alec Machiels | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Director Compensation”. As printed: 492,465. Filing ↗machine: span 499827–500036 |
| 18 | Section 08, Paul Fonteyne | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Director Compensation”. As printed: 487,465. Filing ↗machine: span 494756–494965 |
| 19 | Section 08, Stephanie Monaghan O'Brien | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Director Compensation”. As printed: 484,965. Filing ↗machine: span 504917–505126 |
| 20 | Section 08, A. Sinclair Dunlop | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Director Compensation”. As printed: 477,465. Filing ↗machine: span 489685–489894 |
| 21 | Section 08, Cedric Francois | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 08, Craig Wheeler | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 23 | Section 08, Keli Walbert | DEF 14A | 2025-04-23 | 0000950170-25-056966 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 24 | Section 06, 2025 vote | Form 8-K | 2025-06-04 | 0001193125-25-134886 | Item 5.07 · say-on-pay result. As reported: 94.8% (votes for as printed: 75,901,920). Filing ↗ |
| 25 | Section 06, 2024 vote | Form 8-K | 2024-06-05 | 0001193125-24-155179 | Item 5.07 · say-on-pay result. As reported: 89.88% (votes for as printed: 93,573,357). Filing ↗ |
| 26 | Section 06, 2023 vote | Form 8-K | 2023-06-01 | 0001193125-23-158943 | Item 5.07 · say-on-pay result. As reported: 93.45% (votes for as printed: 94,979,579). Filing ↗ |
| 27 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 28 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 29 | Section 09b board cost (computed) | Computed | — | — | Cash 441,250 + equity 999,960 + all other 0 = 1,441,210, summed across the director compensation table rows.machine: formula: Σ = 1,441,210 |
| 30 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗ |
| 31 | Madrigal Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001308179-26-000352 | CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952 |
| 32 | Corcept Therapeutics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 33 | Insmed Incorporated, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 34 | Blueprint Medicines Corporation, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 35 | Neurocrine Biosciences, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 36 | Ionis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗ |
| 37 | Biocryst Pharmaceuticals, Inc, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in Biocryst Pharmaceuticals, Inc's own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 38 | Apellis Pharmaceuticals, Inc. (subject), Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 39 | Axsome Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 40 | Intra-Cellular Therapies, Inc., Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 41 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 42 | ACADIA Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗ |
| 43 | Alkermes plc, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 44 | Section 10a, Neurocrine Biosciences reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences's most recent proxy was read; its disclosed peer group does not include Apellis Pharmaceuticals, Inc.. Filing ↗ |
| 45 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc. names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 46 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 47 | Section 10a, Axsome Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics, Inc. names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 48 | Section 10a, Intra-Cellular Therapies, Inc. reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies, Inc. names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 49 | Section 10a, Biocryst Pharmaceuticals, Inc reciprocity | DEF 14A | — | 0001628280-26-026822 | Biocryst Pharmaceuticals, Inc names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 50 | Section 10a, Ionis Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals names Apellis Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 51 | Section 10a, Insmed Incorporated reciprocity | DEF 14A | — | 0001104506-26-000022 | Insmed Incorporated's most recent proxy was read; its disclosed peer group does not include Apellis Pharmaceuticals, Inc.. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Apellis Pharmaceuticals, Inc. Executive Compensation Report
$1,500